Minimizing Hypoglycemia While Maintaining Glycemic Control in Diabetes

Heller, Simon

doi:10.2337/db08-1195

Cited by 34 publications

(16 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With respect to the latter, a history of severe hypoglycemia should prompt consideration of a substantial change in the treatment regimen and a history of hypoglycemia unawareness should prompt consideration of a 2-to 3-week period of scrupulous avoidance of hypoglycemia with the anticipation that awareness of hypoglycemia will return (30 -32). Minimizing the risk of hypoglycemia while maintaining meaningful glycemic control is a challenge for people with diabetes and their caregivers, which is addressed in detail separately (44). Perspective on hypoglycemia in diabetes.…”

Section: Risk Factors For Hypoglycemia In Diabetesmentioning

confidence: 99%

The Barrier of Hypoglycemia in Diabetes

2008

View full text Add to dashboard Cite

Section: Risk Factors For Hypoglycemia In Diabetesmentioning

confidence: 99%

The Barrier of Hypoglycemia in Diabetes

2008

View full text Add to dashboard Cite

“…The use of insulin analogues combined with frequent or even continuous glucose monitoring has significantly improved day-to-day control of glycaemia. However, a walk-away device that monitors plasma glucose and automatically adjusts insulin delivery accordingly is still some way off despite recent encouraging developments (Heller 2008, Tamborlane et al 2008. Treatment of T2DM relies largely on the use of drugs that lower hepatic glucose output (metformin), stimulate insulin secretion (sulphonylureas) or improve insulin action via stimulation of the PPARg transcription factor (glitazones).…”

Section: Therapeutic Targets In the Insulin Signalling Pathwaymentioning

confidence: 99%

The molecular basis of insulin-stimulated glucose uptake: signalling, trafficking and potential drug targets

Leney¹,

Tavaré²

2009

Journal of Endocrinology

136

View full text Add to dashboard Cite

The search for the underlying mechanism through which insulin regulates glucose uptake into peripheral tissues has unveiled a highly intricate network of molecules that function in concert to elicit the redistribution or 'translocation' of the glucose transporter isoform GLUT4 from intracellular membranes to the cell surface. Following recent technological advances within this field, this review aims to bring together the key molecular players that are thought to be involved in GLUT4 translocation and will attempt to address the spatial relationship between the signalling and trafficking components of this event. We will also explore the degree to which components of the insulin signalling and GLUT4 trafficking machinery may serve as potential targets for the development of orally available insulin mimics for the treatment of diabetes mellitus.

show abstract

“…Insulin preparation as a prodrug is likely to reduce immunogenicity and proteolysis when injected [29]. Moreover, a high dosage might be made possible without incurring a severe risk of hypoglycemia, which is a major concern in exogenous insulin replacement therapy [32,33].…”

Section: Discussionmentioning

confidence: 99%